QSAM Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QSAM research report →
Price Chart
About the company
Based in Austin, Texas, QSAM Biosciences, Inc. is dedicated to advancing nuclear medicine for cancer and related illnesses. A key component of their pipeline is CycloSam (Samarium-153 DOTMP), a radiopharmaceutical currently in clinical development that specifically targets bone.
- CEO
- Douglas R. Baum
- IPO
- 2012
- Employees
- 4
- HQ
- Austin, TX, US
Get TickerSpark's AI analysis on QSAM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.44K
- P/E
- -6.69
- PEG
- -0.09
- P/S
- 0.00
- P/B
- 43.58
- EV/EBITDA
- -0.00
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 1617.91%
- ROIC
- -579.91%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-3,942,510
- Net Income
- $-4,393,126+27.7%
- EPS
- $-1.24+64.1%
- OCF Growth
- -5.0%
- FCF Growth
- -5.0%
- 52W High
- $16600.00
- 52W Low
- $4.10
- 50D MA
- $649.00
- 200D MA
- $166.26
- Beta
- 1.81
- RSI (14)
- 69
- Avg Volume
- 6.09K
No earnings-call transcripts are available for QSAM yet.
- Free Float
- 100.0%
- Shares Outstanding
- 2.22K
- Float Shares
- 2.22K
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 2, 24 | Piazza C Richard | sell | 188 |
| May 2, 24 | Baum Douglas R | sell | 188 |
| May 2, 24 | Link Jr. Charles J | sell | 41 |
| May 2, 24 | Nelson Christopher M. | sell | 91 |
| May 2, 24 | Sax Adriann | sell | 5 |
| May 2, 24 | King Adam | sell | 11 |
| Jan 15, 23 | Checkmate Strategic Capital 2, LLC | other | 50,000 |
| Dec 19, 23 | Checkmate Strategic Capital 2, LLC | other | 50,000 |
| Feb 6, 24 | Checkmate Strategic Capital 2, LLC | other | 156 |
| Feb 6, 24 | Baum Douglas R | other | 1,302 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our QSAM coverage
Recent articles, reports, and earnings notes.
No research on QSAM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate QSAM report →QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
globenewswire.com · Apr 16
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform
globenewswire.com · Feb 7
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
globenewswire.com · Feb 7
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
globenewswire.com · Nov 14
Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam®
prnewswire.com · Nov 13
QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
globenewswire.com · Aug 16
QSAM Biosciences to Present at the Emerging Growth Conference on Wednesday, January 25, 2023
globenewswire.com · Jan 23
QSAM Biosciences Announces FDA Clearance of IND for Samarium-153 DOTMP (CycloSam®), an Investigational Radiopharmaceutical for the Treatment of Bone Cancer
globenewswire.com · Aug 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.